NASDAQ:SYRE Spyre Therapeutics Q3 2024 Earnings Results & Report $80.45 -5.45 (-6.34%) Closing price 04:00 PM EasternExtended Trading$82.72 +2.27 (+2.83%) As of 07:30 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more. Spyre Therapeutics missed analyst earnings expectations in its Q3 2024 results, released November 7, 2024. The company reported EPS of -$1.36 versus the -$0.80 consensus estimate. Research:ProfileEarnings HistoryForecast Earnings Announcement Details QuarterQ3 2024Report DateNovember 7, 2024TimeAfter Market ClosesConference Call4:00 PM ET Spyre Therapeutics EPS ResultsActual EPS-$1.36Consensus EPS -$0.80Beat/MissMissed by -$0.56One Year Ago EPSN/AEPS Beat Rate5 of last 8 quartersSpyre Therapeutics Revenue ResultsActual RevenueN/AExpected RevenueN/ABeat/MissN/AYoY Revenue GrowthN/AUpcoming EarningsSpyre Therapeutics' Q3 2026 earnings is estimated for Tuesday, November 3, 2026, based on past reporting schedules, with a conference call scheduled on Friday, November 6, 2026 at 4:00 PM ET. Check back for transcripts, audio, and key financial metrics as they become available.Conference Call ResourcesPress Release (8-K)Quarterly Report (10-Q)Earnings HistoryCompany ProfilePowered by Earnings DocumentsPress Release(8-K)Quarterly report(10-Q) Spyre Therapeutics Q3 2024 Earnings FAQ Did Spyre Therapeutics beat earnings estimates for Q3 2024? Spyre Therapeutics (NASDAQ:SYRE) reported earnings of -$1.36 per share for Q3 2024, missing the consensus estimate of -$0.80. The report was announced on Thursday, November 7, 2024. When is Spyre Therapeutics' next earnings date? Spyre Therapeutics' next earnings date is estimated for Tuesday, November 3, 2026. MarketBeat tracks confirmed and estimated earnings dates for Spyre Therapeutics on the company's earnings history page. Spyre Therapeutics Earnings HeadlinesSpyre Therapeutics (SYRE) Completed A $350 Million Public Stock OfferingOctober 8, 2026 | finance.yahoo.comSpyre Therapeutics Sinks 14% on Upsized $350 Million Stock Offering Priced Below MarketOctober 6, 2026 | finance.yahoo.comDo NOT Buy SpaceX – Do This InsteadSpaceX just went public - and Whitney Tilson, Harvard MBA and 30-year Wall Street veteran, says buying in could be a costly mistake. He calls it among the most overhyped, overvalued large-cap offerings ever pushed onto everyday investors. Tilson believes a rare economic event is approaching - one with serious consequences for your portfolio this summer. He has prepared a free analysis outlining what he sees and the specific steps he recommends taking now.October 13 at 1:00 AM | Stansberry Research (Ad)Spyre Therapeutics Prices $350 Million Common Stock Offering; Shares Down Pre-BellOctober 6, 2026 | finance.yahoo.comSpyre Therapeutics Prices $350 Mln Public Offering Of SharesOctober 6, 2026 | rttnews.comSpyre Therapeutics prices $350M public offering at $85 per shareOctober 6, 2026 | msn.comSee More Spyre Therapeutics Headlines Get Earnings Announcements in your inboxWant to stay updated on the latest earnings announcements and upcoming reports for companies like Spyre Therapeutics? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Spyre Therapeutics and other key companies, straight to your email. Email Address About Spyre TherapeuticsSpyre Therapeutics (NASDAQ:SYRE) is a clinical-stage biotechnology company focused on developing antibody therapeutics for inflammatory bowel disease (IBD), including ulcerative colitis and Crohn’s disease. The company is working to create next-generation biologic medicines intended to address significant treatment needs in these chronic gastrointestinal conditions. Spyre’s pipeline includes programs directed at validated inflammatory pathways, including interleukin-23 (IL-23) and tumor necrosis factor-like ligand 1A (TL1A). Its research approach emphasizes antibody engineering, with the goal of developing therapies that may offer durable activity, convenient dosing, and potential use in combination treatment regimens. The company’s programs remain in clinical development and are subject to ongoing evaluation for safety and effectiveness. The company was formed through a transaction involving Aeglea BioTherapeutics and Spyre Therapeutics and began trading under the name Spyre Therapeutics and the Nasdaq symbol SYRE in 2023. Spyre is headquartered in the United States and conducts its drug discovery and development activities through research, clinical, and corporate operations. Its leadership includes Chief Executive Officer and President Cameron Turtle, Ph.D.View Spyre Therapeutics ProfileRead more More Earnings Resources from MarketBeat Earnings Tools Today's Earnings Tomorrow's Earnings Next Week's Earnings Upcoming Earnings Calls Earnings Newsletter Earnings Call Transcripts Earnings Beats & Misses Corporate Guidance Earnings Screener Latest Articles A Chinese Rival Just Spooked Memory Stocks—How Worried Should Micron Investors Be?Surgical Precision, Sustainable Returns: Johnson & Johnson Secures Its Cash Flow RunwayJPMorgan Earnings Miss Estimates But Reveal Broad-Based StrengthAmazon's $220 Billion AI Bet Is Getting Bigger—Can Earnings Justify the Spending?A Silent Winner: Texas Instruments Anchors the AI SupercycleDelta's Guidance Cut Could Spell Trouble for the Airline Industry5 Retail Picks to Watch as the Holiday Shopping Season Nears Upcoming Earnings Bank of America (10/14/2026)BlackRock (10/14/2026)Morgan Stanley (10/14/2026)Progressive (10/14/2026)Fastenal (10/14/2026)ASML (10/14/2026)Interactive Brokers Group (10/15/2026)Marsh & McLennan Companies (10/15/2026)The PNC Financial Services Group (10/15/2026)Charles Schwab (10/15/2026) Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
